vs
Side-by-side financial comparison of 9F Inc. (JFU) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
9F Inc. is the larger business by last-quarter revenue ($81.4M vs $66.0M, roughly 1.2× SOLENO THERAPEUTICS INC). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs -105.9%, a 145.3% gap on every dollar of revenue. SOLENO THERAPEUTICS INC produced more free cash flow last quarter ($43.5M vs $2.7M).
9F Inc. is a leading digital financial technology platform based in China, offering consumer finance, wealth management, and insurance brokerage services primarily to retail and small business customers across domestic markets. It leverages big data and artificial intelligence to deliver tailored, accessible financial solutions that meet diverse user needs across multiple fintech segments.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
JFU vs SLNO — Head-to-Head
Income Statement — Q4 FY2022 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $81.4M | $66.0M |
| Net Profit | $-86.2M | $26.0M |
| Gross Margin | 19.3% | 98.3% |
| Operating Margin | -26.8% | 33.5% |
| Net Margin | -105.9% | 39.4% |
| Revenue YoY | — | — |
| Net Profit YoY | — | 134.0% |
| EPS (diluted) | — | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $66.0M | ||
| Q2 25 | — | $32.7M | ||
| Q1 23 | $81.4M | — |
| Q3 25 | — | $26.0M | ||
| Q2 25 | — | $-4.7M | ||
| Q1 23 | $-86.2M | — |
| Q3 25 | — | 98.3% | ||
| Q2 25 | — | 97.9% | ||
| Q1 23 | 19.3% | — |
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | -20.0% | ||
| Q1 23 | -26.8% | — |
| Q3 25 | — | 39.4% | ||
| Q2 25 | — | -14.4% | ||
| Q1 23 | -105.9% | — |
| Q3 25 | — | $0.47 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $335.8M | $498.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $530.1M | $494.8M |
| Total Assets | $625.0M | $599.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $498.9M | ||
| Q2 25 | — | $286.8M | ||
| Q1 23 | $335.8M | — |
| Q3 25 | — | $494.8M | ||
| Q2 25 | — | $240.1M | ||
| Q1 23 | $530.1M | — |
| Q3 25 | — | $599.9M | ||
| Q2 25 | — | $332.3M | ||
| Q1 23 | $625.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $43.5M |
| Free Cash FlowOCF − Capex | $2.7M | $43.5M |
| FCF MarginFCF / Revenue | 3.3% | 65.8% |
| Capex IntensityCapex / Revenue | 8.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $43.5M | ||
| Q2 25 | — | $-12.6M | ||
| Q1 23 | $9.2M | — |
| Q3 25 | — | $43.5M | ||
| Q2 25 | — | $-12.6M | ||
| Q1 23 | $2.7M | — |
| Q3 25 | — | 65.8% | ||
| Q2 25 | — | -38.6% | ||
| Q1 23 | 3.3% | — |
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 23 | 8.0% | — |
| Q3 25 | — | 1.67× | ||
| Q2 25 | — | — | ||
| Q1 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
